Short-Term Efficacy of Celiac Plexus Block Combined with Interstitial Permanent Implantation of 125I Seeds in Treatment of Advanced Pancreatic Cancer
10.3971/j.issn.1000-8578.2024.23.1161
- VernacularTitle:腹腔神经丛阻滞术联合125I粒子组织间植入治疗晚期胰腺癌的近期疗效
- Author:
Zunqian KE
1
;
Zhihong YIN
;
Dong ZHOU
;
Xiaodong ZHU
;
Hao NIE
;
Shuihong HU
;
Yong ZENG
;
Jiahua ZOU
Author Information
1. 438021 黄冈,黄冈市中心医院肿瘤中心
- Keywords:
Pancreatic cancer;
Celiac plexus block;
125I particles
- From:
Cancer Research on Prevention and Treatment
2024;51(7):583-587
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the short-term efficacy of celiac plexus block combined with the interstitial permanent implantation of 125I seeds in the treatment of advanced pancreatic cancer(inoperable locally advanced and metastatic pancreatic cancers).Methods A total of 100 patients with advanced pancreatic cancer were selected and treated with celiac plexus block combined with the interstitial permanent implantation of 125I seeds under CT guidance.Pain relief and changes in the tumor marker CA19-9 were assessed on the seventh day,the first and third months after surgery.In the third month after surgery,tumor size was assessed by CT.Results Among the 100 patients with advanced pancreatic cancer,complete response(CR)was found in 12 cases,partial response(PR)in 78 cases,stable disease in five cases,and progression of disease in five cases three months after surgery.The CA19-9 level and the sum of short and long tumor diameters were significantly decreased(both P<0.01).A total of 100 patients had severe pain before treatment(visual analogue scale(VAS)):7-10 points),59 patients reported pain disappearance(VAS:0 points),35 patients had mild pain(VAS:1-3 points),and six patients experienced moderate pain(VAS:4-6 points)in the third month after treatment.The pain relief rate was 100%.Conclusion Celiac plexus block combined with the interstitial permanent implantation of 125I seeds has good short-term efficacy and can effectively improve short-term pain in patients with advanced pancreatic cancer.
